Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology. "LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion," said Geordan Pursglove, Chairman and Chief Exe

BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The Company purchased 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) for a total of approximately $2.6 million as part of its strategy to strengthen its treasury position and expand its ability to transact across multiple mediums of exchange. Cryptocurrency now totals approximately 43.6 percent of LIXTE's treasury holdings. Recently, the Company's Board of Directors approved an increas

Unlocking a New Era in Cancer TreatmentDenver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, underscores the scientific significance of LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage biotechnology company developing first-in-class inhibitors targeting protein phosphatases to enhance cancer treatment. LIXTE's lead compound, LB-100, is the world's only clinical-stage inhibitor of protein phosphatase 2A (PP2A). This unique "off switch" mechanism positions LB-100 as a next-generation "cancer power-up" capable of transforming how traditional

-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in Cancer (July 2025, Vol. 11, No. 7, https://doi.org/10.1016/j.trecan.2025.04.009) describing the first international conference on activation of oncogenic signaling as a cancer treatment strategy. The landmark meeting was co-sponsored by LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) and co-organized by Professor Rene Bernards, and board member of LIXTE. At the conference, compelling new data was presented showing that LIXTE's lead compound LB-100 can medi

DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. The company is advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited treatment options. The company's lead compound, LB-100, is being evaluated in several investigator-led clinical studies aimed at enhancing the effectiveness of both chemotherapy and immunother

DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Cancer editorial titled "Too Much of a Good Thing", which explores a counterintuitive cancer therapy approach that underscores the growing promise of its lead compound, LB-100 Nature. The editorial underscores LIXTE's first-in-class PP2A inhibitor, LB-100, and its revolutionary potential to exploit onco

-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific Journal Nature  that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. "This has been a trans

DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing breakthrough cancer therapeutics, announced today that its Board of Directors approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including Bitcoin and potentially other digital assets. The decision underscores the company's commitment to strategic capital allocation and long-term shareholder value creation. Under the newly adopted policy, up to 25% of LIXTE's corporate

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital allocation initiative to acquire cryptocurrency as part of its corporate treasury. The Board approved allocation of up to 25 percent of its treasury to cryptocurrencies, including Bitcoin and potentially other digital assets as it deems appropriate. The timing and size of any such transactions will depend on prevailing market conditions and other strategic considerations. LIXTE will continue to closely monitor developments in the digital asset sp

-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv

Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors. Professor Bernards will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Professor Bernards to our Board of Directors and we look forward to his insight and

EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ("Lixte" or the "Company") (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D. Dr. John S. Kovach, the Founder and Chief Executive Officer of Lixte, commented, "Gil Schwartzberg has played an important role advising and supporting Lixte since its inception. We are pleased to be welcoming Mr. Schwartzberg to our Board of Directors." Dr. Kovach continue

SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)